Opendata, web and dolomites

THERAPROBES SIGNED

Biodegradable fluorescent nanoprobes for early detection of (pre)malignant lesions of the gastrointestinal tract

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 THERAPROBES project word cloud

Explore the words cloud of the THERAPROBES project. It provides you a very rough idea of what is the project "THERAPROBES" about.

subtle    chance    nanoprobes    clinical    asymptomatic    sensitivity    25    poor    true    routine    80    time    near    random    lesion    decrease    scales    therapeutic    treatments    33    lack    tumor    light    intervention    fsn    misses    ablation    progress    survival    solely    white    marker    resection    inter    active    unmet    detection    detect    gastrointestinal    site    successful    accurately    clinically    agents    rate    recur    tract    gitract    risk    vascular    diagnosis    patients    sampling    endoscopic    applicable    tremendous    gi    appearance    outcomes    silica    visualization    diagnosing    optical    specificity    curative    directing    minus    permeability    malignant    rates    operator    errors    impacting    inherent    patient    imaging    requiring    fsns    disease    surveillance    accumulate    diagnostic    treatment    miss    lesions    variability    accuracy    sites    50    paradigm    biopsy    strategy    sensitive    regular    progression    size    symptomatic    aggressive    biodegradable    delineation    contrast    fluorescent    accurate    improves    endoscopy    physician    ubiquitously    detected    negatively    reliably    amenable    compromises    life    augmented    systemic    critical    quality   

Project "THERAPROBES" data sheet

The following table provides information about the project.

Coordinator
PERCUROS BV 

Organization address
address: PLESMANLAAN 1
city: LEIDEN
postcode: 2333 BZ
website: www.percuros.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 187˙572 €
 EC max contribution 187˙572 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PERCUROS BV NL (LEIDEN) coordinator 187˙572.00

Map

 Project objective

Accurate diagnosis of (pre)malignant gastrointestinal (GI)-tract lesions is critical for patient survival. Early detection of asymptomatic disease of the GItract improves the chance of curative intervention by 50−80% as compared to poor five-year survival rates for symptomatic advanced malignant disease. Regular endoscopic surveillance in high-risk patients misses 25% of (pre)malignant lesions – the most clinically relevant marker for malignant progression. This clinically significant miss rate is due to the subtle appearance of such lesions under white-light endoscopy and sampling errors inherent to a random-biopsy surveillance paradigm, which increases inter-operator variability and compromises diagnostic accuracy. Even when malignant disease is detected, lack of sensitive contrast agents compromises delineation of the true extent of the lesion. These factors decrease the physician’s ability to achieve successful therapeutic intervention through resection or ablation. About 33% of GI-tract lesions progress or recur at or near the therapeutic site, commonly requiring aggressive yet often non-curative, systemic treatments negatively impacting the patients’ quality of life. There is an unmet clinical need for endoscopic optical imaging approaches that reliably detect those lesions with high sensitivity and specificity. To develop a clinically viable strategy, I propose to use biodegradable, fluorescent silica nanoprobes (FSN) that provide real-time visualization of the lesions over a range of scales during routine endoscopy. Since FSNs accumulate at the tumor sites solely due to their size and increased vascular permeability, no active targeting is needed, making these imaging agents ubiquitously applicable. Endoscopy augmented with FSNs has tremendous potential for better outcomes particularly in high-risk patients by accurately diagnosing and directing treatment specifically to early lesions at a time when patients are amenable to curative therapeutic intervention.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERAPROBES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERAPROBES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Drought (2020)

Drought coping strategies in southern Africa 1966-2016

Read More  

UNITE (2019)

Unification Through Law: The Court of Justice of the European Union as Cultural-Moral Agent

Read More  

COLEX (2019)

Coopetition and Legislation in the Spanish Netherlands (1598-1665)

Read More